about
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerBinding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealedMultidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane VesiclesDifferential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissueA phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursApplication of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.Comparative adverse effect profiles of platinum drugs.Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.Emerging roles of metal solute carriers in cancer mechanisms and treatment.In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity.Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro.Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro.Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry.Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New ZealandPreparation, Characterization, DNA Binding, andin VitroCytotoxicity of the Enantiomers of the Platinum(II) ComplexesN-Methyl-,N-Ethyl- andN,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II)COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMAIN VITRORapid biotransformation of satraplatin by human red blood cells in vitroPlasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in miceTamoxifen and chemotherapy for refractory metastatic malignant melanomaPhase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancerCarboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer
P50
Q24642049-3EE2FD99-C1F2-45E8-BA0D-5426B1803E61Q27702546-93B9496A-EB61-4B11-9D16-351D6312B157Q28546068-3F53D6EF-2544-4491-9227-B058F7CA5DA5Q28564651-60084CF8-0875-47F1-825A-BBCC916D6B67Q33397528-E38BA2E8-EE1C-4B09-97DA-B83A6298DD28Q33404024-5A3E902B-92CA-43C7-ACBB-F4D292AB22BFQ33432502-92C36F89-A662-4606-8E75-8EBFEFAB57C2Q33495298-BDCFD7DD-3676-4826-86C5-CBFF8E1D1DB3Q33669579-8D64AF40-1DE5-4BF4-84CD-F56CC82111A3Q34125846-CB1519C3-6EE8-4274-B955-9BEC8FCBF73FQ34134062-220E232C-D1A8-4922-8FA4-72E5D316FDC3Q34764827-3D591FF0-4485-448A-AF3E-8A8C4DC6E052Q35025710-CAF68404-8CE2-49A8-AE98-8C7BB87C1356Q35163699-E5BA25AB-822C-4E23-AAFA-48B056B1D3CEQ35978030-D03BCC19-D9D1-495A-A0DF-A7A4A498886EQ36467231-2A82ABD9-0755-4233-8DA1-B7CCD4607993Q37340539-D26071BD-D1D8-4372-B92F-A921C8762BA2Q37448398-4AC64F43-573C-4D93-88B2-A7DBF00C437CQ37694429-00852128-9167-4B6B-9A0C-63244ECA43A5Q37808216-417CD3C0-1E9E-45D4-AB7D-BD5D95A06A52Q37887909-5A9646AA-2492-49C7-A055-6ED980153224Q38026121-34A4F73A-DE75-441E-9668-D9000C906F93Q38216940-AB46DE2D-1984-4C3D-A961-FF9639B159ECQ40047241-24843622-1D50-401E-8186-C5843B543DAAQ42482333-9B9DE5C3-B597-4257-8E93-6C996D9454A5Q42712071-098EB21B-3D15-4CBF-98C2-11B19A4EC3D4Q43643253-56BFD537-2EBF-47AE-AFED-A3DD9E25A037Q45998363-BFBBAC82-E110-4D36-A491-27B98CCF7C65Q46711988-4AFC1E5E-A3BA-43BB-BC38-9D898EE1319DQ51203395-6B3FA5BA-CF25-4B15-8478-279D2F85D686Q51788292-78BDADB0-6D3D-4241-A5E9-318E20995F0AQ52620105-10993917-36DB-4837-9166-B5853F2460E8Q57064738-1B9F0DB9-8356-42DC-9781-93C78AC79634Q60300150-52BCE4A2-997F-4353-9B64-41C5AD2D4072Q62232227-97B26605-AC22-4C87-93DD-4DB7D9DFC37EQ62232302-C75D90A9-39D2-4B7E-B50B-0D2A2CB7CB27Q68033249-52AC48DD-E994-4615-8FEE-77829786C3FEQ70520527-8E951CA2-1E8C-455E-80AF-6A1EE5AA8F61Q73535621-A09A1C97-B5EC-4697-8652-2440CF3B03CBQ74572631-2B001D05-20E0-4124-B46B-C562B22B4614
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark J McKeage
@ast
Mark J McKeage
@en
Mark J McKeage
@es
Mark J McKeage
@nl
type
label
Mark J McKeage
@ast
Mark J McKeage
@en
Mark J McKeage
@es
Mark J McKeage
@nl
prefLabel
Mark J McKeage
@ast
Mark J McKeage
@en
Mark J McKeage
@es
Mark J McKeage
@nl
P106
P1153
7003605859
P31
P496
0000-0002-7329-5503